ARS Pharmaceuticals Inc. (SPRY), undeterred by its previous regulatory setback, has mounted a resolute second effort to secure FDA approval for its investigational product neffy.
Having completed the required studies and resubmitted its New Drug Application for neffy with additional data and refinements, the company is back at the FDA's doorstep, determined to cross the elusive finish line to commercialization.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com